For many people living with arthritis or nagging joint pain, glucosamine has become a go-to supplement for everyday comfort and mobility support. It is easy to find on store shelves, frequently paired with chondroitin, and often marketed as a way to help protect cartilage and keep joints moving smoothly. With nearly 59 million Americans diagnosed with arthritis and research suggesting that real numbers of joint pain may be significantly higher, interest in joint supplements has never been greater. That is why a new study exploring a potential connection between glucosamine and dementia progression is attracting attention among people searching for safe, effective options for joint health.

The research, published in Nature Metabolism, looked at whether glucosamine use might be linked to how quickly dementia develops or worsens. The central question was not about whether glucosamine could cause Alzheimer’s disease or related dementias, but whether it might influence the course of these conditions once they are already present. The article highlights that glucosamine is one of the most popular supplements among older adults, which makes any possible link to cognitive health important to understand.

The study team, which included biochemist Ramon C. Sun, Ph.D., at the University of Florida College of Medicine, began by analyzing patient health records from people seen at University of Florida Health facilities between 2012 and 2024. They focused on two groups. The first group included patients diagnosed with Alzheimer’s disease and related dementias, often referred to collectively as ADRD. The second included people with mild cognitive impairment, or MCI, which is sometimes considered an early stage of cognitive decline that does not yet meet criteria for dementia.

Within each group, about 8% of people reported using glucosamine. That worked out to 1,896 individuals with ADRD and 2,750 with mild cognitive impairment. When researchers looked more closely at these health records, they found that people with mild cognitive impairment who took glucosamine were 25% more likely to progress to dementia during the study period. In the group that already had Alzheimer’s disease or related dementias, glucosamine use was associated with a 25% higher likelihood of death over the 10-year analysis window.

These numbers understandably sound alarming at first glance, yet the researchers and outside experts emphasize an important distinction. The study identified an association between glucosamine use and outcomes such as dementia progression and mortality. It did not prove that glucosamine caused these changes. Many other factors might be involved, so caution and further research are required before drawing firm conclusions or changing medical practice.

To better understand what might be happening on a biological level, the investigators went beyond medical records and turned to laboratory models. They worked with genetically modified mice designed to mimic aspects of Alzheimer’s disease, then studied how glucosamine affected a cellular process known as glycosylation. Glycosylation occurs when cells attach sugar chains, known as glycans, to proteins. This process helps shape how proteins fold, where they travel inside cells, and how they function. In the brain, it influences how neurons communicate and how learning and memory operate.

In these mouse models, glucosamine increased glycosylation and was linked with worse memory performance. When the researchers reduced this glycosylation activity, the mice showed improved memory. The team then looked at human brain tissue and found that people with Alzheimer’s disease had higher levels of glycosylation compared with individuals without the condition. They referred to this pattern as hyperglycosylation and noted that it involved proteins connected to amyloid and tau, both of which are strongly associated with dementia.

Sun explained that this suggests glycosylation might be a shared feature in Alzheimer’s disease rather than something limited to a single experimental model. In this view, a brain already affected by dementia has an altered biological environment in which normal processes, including glycosylation, behave differently. Glucosamine appears to feed into the pathway the body uses to build these sugar chains, and it does so in a way that bypasses a major regulatory checkpoint. That means it can add extra raw material directly to the system.

In a healthy brain, Sun notes, this additional input from a glucosamine supplement does not seem to matter. In a brain already affected by Alzheimer’s disease or related dementias, the pathway appears to be overactive. Adding more fuel through glucosamine may further boost the production of sugar chains that attach to key neuronal proteins. When these proteins become over-glycosylated, it may interfere with how neurons send signals and communicate, potentially worsening cognitive problems.

Although this mechanistic explanation is compelling, both Sun and outside experts underscore that these findings are preliminary. They highlight a plausible biological pathway and a correlation in patient data, yet they do not amount to proof that glucosamine speeds dementia or shortens life in people with cognitive conditions. Sun argues that the next logical step would be to conduct a prospective clinical trial that follows people over time and controls for many other variables, which could provide clearer evidence about whether glucosamine plays a direct role.

Neurologist Clifford Segil, D.O., of Providence Saint John’s Health Center, offers a similar perspective. He describes the findings as interesting and thought-provoking but not strong enough to change how he cares for patients with arthritis who use glucosamine for joint pain. He points out that much of the evidence comes from animal models and genetic manipulation of metabolic pathways, which does not directly translate to outcomes in humans with memory loss. In his view, the study helps raise new questions rather than delivering definitive answers.

It is also worth keeping the study population in mind. Sun notes that the observed concerns involved people whose brains were already affected by cognitive impairment or dementia. The analysis did not include healthy people without these conditions, and the researchers do not suggest that glucosamine poses a problem for those individuals based on current evidence. This is key for older adults who take glucosamine for joint health but have no known cognitive issues, since the study does not address that group directly.

At the same time, the work offers a broader reminder about how to think about dietary supplements. Sun emphasizes that supplements are not inert or neutral. They enter the body’s metabolic pathways and can interact with existing health conditions in complex ways. Something that appears neutral or even beneficial at one stage of health may behave differently in another context, such as when the brain is already undergoing changes tied to dementia.

For people living with mild cognitive impairment or dementia who are currently using glucosamine, the article suggests a balanced, practical step: bring it up at the next appointment with a healthcare professional. That conversation can help weigh joint pain relief against potential, still uncertain cognitive risks, and consider alternative strategies if needed. It may also be an opportunity to review all supplements and medications to ensure they continue to make sense given a person’s overall health profile.

One detail I found striking in this work is how a seemingly straightforward joint supplement intersects with an intricate brain process like glycosylation. It illustrates how interconnected the body’s systems are and why careful study is essential before making assumptions about safety or benefit. The message throughout the article is not to panic, but to stay informed, keep perspective, and avoid abrupt changes without professional guidance. More research is needed before experts can recommend specific changes for the general public or even for people with cognitive conditions.

For now, the key takeaway is measured and calm. People without cognitive issues who take glucosamine for joint pain do not appear to be the focus of this concern. Individuals with mild cognitive impairment or dementia who use glucosamine may want to bring these findings to their clinicians for personalized advice. Above all, it is important to remember that dietary supplements are meant to support the diet, not to treat, diagnose, mitigate, prevent, or cure disease. Anyone who is pregnant, nursing, or considering supplements for a child should seek guidance from a qualified healthcare provider before starting or stopping any product.

Read more at https://www.prevention.com/health/a73931561/glucosamine-dementia-study/